Literature DB >> 21348770

Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Debra L Bogen1, James M Perel, Joseph C Helsel, Barbara H Hanusa, Matthew Thompson, Katherine L Wisner.   

Abstract

BACKGROUND AND OBJECTIVES: Breastfeeding, a public health priority, improves outcomes for infants. Methadone is dispensed as a racemic mixture; R-methadone is the active enantiomer. Pharmacologic data for R-methadone in breastmilk could improve risk-benefit decision-making for treatment of lactating women. This study estimated infant exposure to R- and S-methadone via breastmilk by theoretic infant dose (TID) and relative infant dose (RID) and reported the milk-to-maternal plasma (M/P) ratio.
METHODS: Women treated with methadone doses of 40-200 mg/day (mean, 102 mg/day) provided concomitantly collected plasma and breastmilk samples 1-6 days after delivery. Most (16 of 20) samples were taken at the time of peak maternal plasma levels; thus infant exposure estimates are for maximum possible exposure. Concentrations of R- and S-methadone were measured in maternal plasma and breastmilk; M/P ratio, TID, and RID were calculated for each enantiomer and total methadone.
RESULTS: The 20 participants were 18-38 years old and publicly insured; a quarter did not complete high school, and only one was not white. R-Methadone concentration was 1.3-3.0 times that of S-methadone in all breastmilk samples. The mean (SD) R-, S-, and total methadone M/P ratios were 0.52 (0.28), 0.28 (0.15), and 0.40 (0.21), respectively. Mean (range) R-, S-, and total methadone TID were 0.02 mg/kg/day (0.004-0.099), 0.013 mg/kg/day (0.002-0.071), and 0.033 mg/kg/day (0.006-0.170), respectively. Mean (range) RID of R-, S-, and total methadone were 2.7% (0.7-10.1%), 1.6% (0.3-7.2%), and 2.1% (0.52-8.8%), respectively.
CONCLUSIONS: R-Methadone is found in higher concentrations than S-methadone in breastmilk. Even at high methadone doses, breastmilk methadone concentrations were relatively low and support American Academy of Pediatrics recommendations that dose should not be a factor in determining whether women on methadone breastfeed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21348770      PMCID: PMC3228593          DOI: 10.1089/bfm.2010.0060

Source DB:  PubMed          Journal:  Breastfeed Med        ISSN: 1556-8253            Impact factor:   1.817


  47 in total

1.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

2.  A comparison of kangaroo mother care and conventional incubator care for thermal regulation of infants < 2000 g in Nigeria using continuous ambulatory temperature monitoring.

Authors:  O E Ibe; T Austin; K Sullivan; O Fabanwo; E Disu; A M de L Costello
Journal:  Ann Trop Paediatr       Date:  2004-09

3.  Methadone assays in pregnant women and progeny.

Authors:  G Blinick; C E Inturrisi; E Jerez; R C Wallach
Journal:  Am J Obstet Gynecol       Date:  1975-03-01       Impact factor: 8.661

4.  Methadone levels in human milk.

Authors:  J J McCarthy; B L Posey
Journal:  J Hum Lact       Date:  2000-05       Impact factor: 2.219

Review 5.  Treatment of neonatal abstinence syndrome with breast milk containing methadone.

Authors:  Jeanne L Ballard
Journal:  J Perinat Neonatal Nurs       Date:  2002-03       Impact factor: 1.638

6.  Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing.

Authors:  E J Begg; T J Malpas; L P Hackett; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

7.  Breastfeeding rates among mothers of infants with neonatal abstinence syndrome.

Authors:  Elisha M Wachman; John Byun; Barbara L Philipp
Journal:  Breastfeed Med       Date:  2010-08       Impact factor: 1.817

Review 8.  Transfer of drugs and other chemicals into human milk.

Authors: 
Journal:  Pediatrics       Date:  2001-09       Impact factor: 7.124

9.  Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.

Authors:  C B Eap; M Bourquin; J Martin; J Spagnoli; S Livoti; K Powell; P Baumann; J Déglon
Journal:  Drug Alcohol Depend       Date:  2000-12-22       Impact factor: 4.492

10.  Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

Authors:  John G Gerber; Robert J Rhodes; Joseph Gal
Journal:  Chirality       Date:  2004-01       Impact factor: 2.437

View more
  6 in total

Review 1.  ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015.

Authors:  Sarah Reece-Stremtan; Kathleen A Marinelli
Journal:  Breastfeed Med       Date:  2015-04       Impact factor: 1.817

Review 2.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

3.  Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Authors:  D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner
Journal:  Psychopharmacology (Berl)       Date:  2012-08-25       Impact factor: 4.530

4.  Corrected QT Interval and Methadone Dose and Concentrations in Pregnant and Postpartum Women.

Authors:  Debra L Bogen; Barbara H Hanusa; James M Perel; Frederick Sherman; Marla A Mendelson; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

5.  Breastfeeding and Methadone Therapy: The Maternal Experience.

Authors:  Jill R Demirci; Debra L Bogen; Yael Klionsky
Journal:  Subst Abus       Date:  2014-04-04       Impact factor: 3.716

Review 6.  Breastfeeding and Opiate Substitution Therapy: Starting to Understand Infant Feeding Choices.

Authors:  Lisa E Graves; Suzanne Turner; Maya Nader; Sucheta Sinha
Journal:  Subst Abuse       Date:  2016-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.